Inguinal Hernia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Inguinal Hernia Market Outlook

Thelansis’s “Inguinal Hernia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Inguinal Hernia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Inguinal Hernia Overview

A hernia is a broad term for the protrusion or bulging of an organ or tissue through an abnormal opening within the body's structure. While hernias come in various types, they typically involve the abdomen. Roughly 75% of hernias occur in the inguinal region. The symptoms of an inguinal hernia can manifest gradually or suddenly, such as with incarceration, when the hernia sac's contents cannot return to the abdomen. In some cases, inguinal hernias might not exhibit symptoms and could be discovered incidentally during routine physical exams. When symptoms are present, patients often experience significant groin pain, sometimes accompanied by a burning, gurgling, or aching sensation due to tissue stretching or tearing around the hernia defect. Certain factors can increase the likelihood of developing an inguinal hernia. One contributing factor is a weakened abdominal wall, which can lead to pressure causing the hernia to form. Additional risk factors encompass:

• Genetic predisposition
• Premature birth
• Cystic fibrosis
• Prior history of inguinal hernia
• Chronic constipation
• Male gender
• Obesity or overweight
• Persistent coughing
• Pregnancy

The most frequent complications from hernia repair include hematomas, bruising around the penile or scrotal area, seromas, and wound infections. Inguinal hernias are much more prevalent in males, with a 9:1 ratio, particularly among men aged 40 to 59. It's estimated that over a quarter of adult men in the United States have a medically recognizable inguinal hernia. In women, a higher incidence of inguinal hernias has been linked to factors such as taller height, chronic cough, umbilical hernias, older age, and rural residence.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: